(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Compassion and Association: Building Significant Connections - 2How the Iran war may affect your money and bills
- 3Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- 4Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- 5Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know
- How food assistance programs can feed families and nourish their dignity
- Audits of 6 Specialty Mixed drinks
- Woman gives birth on roadside after hospital allegedly sent her home: Family
- She was the ultimate '90s fitness influencer. Now she's delivering Uber Eats — and rebuilding her life.
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- Meet the astronauts about to make history on flight around the moon
- How a toxic self-improvement trend with a funny name took over your feed
- One-third of asylum applications by Iranians approved in Germany
